EVL抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: RAMOS cell lysate, Primary antibody: P10443(EVL Antibody) at dilution 1/1000, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 3 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P10443(EVL Antibody) at dilution 1/140. (Original magnification: ×200)    

  
  

EVL (Ena/VASP-like protein) is a member of the Ena/VASP family, which regulates actin cytoskeleton dynamics by interacting with actin filaments and modulating cell motility, adhesion, and morphogenesis. Discovered in the late 1990s, EVL shares homology with Enabled (Ena) and Vasodilator-Stimulated Phosphoprotein (VASP), featuring conserved domains like the EVH1 (Ena/VASP homology 1) and EVH2. which mediate protein-protein interactions and actin binding. EVL localizes to focal adhesions, lamellipodia, and filopodia, where it promotes actin polymerization and coordinates cell migration by antagonizing capping proteins.

EVL antibodies are vital tools for studying its role in cellular processes, including neuronal development, immune cell trafficking, and cancer metastasis. They enable detection of EVL expression, localization, and post-translational modifications (e.g., phosphorylation) via techniques like Western blotting, immunofluorescence, and immunoprecipitation. Dysregulation of EVL is linked to pathological conditions; reduced EVL levels correlate with impaired synaptic plasticity in neurological disorders, while overexpression in cancers may enhance invasive potential. Research using EVL-knockout models or CRISPR-mediated silencing further highlights its importance in embryogenesis and tissue homeostasis. Commercial EVL antibodies are typically raised against conserved epitopes, with validation in specific applications ensuring reliability. Ongoing studies aim to clarify EVL's interplay with signaling pathways (e.g., Rho GTPases) and its potential as a therapeutic target.